Market Assessment
Albireo (ALBO) is a small-market-cap ($423M), commercial-stage biopharma that was publicly listed through a reverse merger with Biodel in November 2016. Its clinical focus on pediatric-orphan liver therapeutics and the development of novel bile acid modulators, ileal bile acid transporter ((IBAT)) inhibitors, are its two unique differentiating clinical qualities.
Elobixibat (formerly A3309) was acquired from AstraZeneca (AZN). It is minimally absorbed into the bloodstream, which is why it has minimal systemic exposure in the body. Elobixibat is a first-in-class, once-daily, orally-available partial IBAT inhibitor that is approved in Japan for the treatment of